Initiating Clinical Trials with Gene Therapies Targeting Neurodegenerative Disorders

Time: 11:45 am
day: Day Two

Details:

  • Clinical Experience with AAV9-based Gene Therapies Targeting
    Neurodegenerative Disorders
  • Interim analysis of the RGX-121 gene therapy first in human study for the treatment of severe Mucopolysaccharidosis Type II
  • Interim analysis of the RGX-111 gene therapy first in human study and a single patient IND for the treatment of severe Mucopolysaccharidosis Type I

Speakers: